Number of the records: 1  

SC-560 and mofezolac isosteres as new potent COX-1 selective inhibitors with antiplatelet effect

  1. 1.
    0570616 - ÚEB 2024 RIV DE eng J - Journal Article
    Šíša, Miroslav - Konečný, L. - Temml, V. - Carazo, A. - Mladěnka, P. - Landa, Přemysl
    SC-560 and mofezolac isosteres as new potent COX-1 selective inhibitors with antiplatelet effect.
    Archiv der Pharmazie. Roč. 356, č. 5 (2023), č. článku e2200549. ISSN 0365-6233. E-ISSN 1521-4184
    R&D Projects: GA MŠMT(CZ) LTC18065
    Institutional support: RVO:61389030
    Keywords : cyclooxygenase * cytotoxicity * docking * platelets * selectivity
    OECD category: Organic chemistry
    Impact factor: 5.1, year: 2022
    Method of publishing: Open access
    https://doi.org/10.1002/ardp.202200549

    Selective cyclooxygenase (COX)-1 inhibitors can be employed as potential cardioprotective drugs. Moreover, COX-1 plays a key role in inflammatory processes and its activity is associated with some types of cancer. In this work, we designed and synthesized a set of compounds that structurally mimic the selective COX-1 inhibitors, SC-560 and mofezolac, the central cores of which were replaced either with triazole or benzene rings. The advantage of this approach is a relatively simple synthesis in comparison with the syntheses of parent compounds. The newly synthesized compounds exhibited remarkable activity and selectivity toward COX-1 in the enzymatic in vitro assay. The most potent compound, 10a (IC50 = 3 nM for COX-1 and 850 nM for COX-2), was as active as SC-560 (IC50 = 2.4 nM for COX-1 and 470 nM for COX-2) toward COX-1 and it was even more selective. The in vitro COX-1 enzymatic activity was further confirmed in the cell-based whole-blood antiplatelet assay, where three out of four selected compounds (10a,c,d, and 3b) exerted outstanding IC50 values in the nanomolar range (9–252 nM). Moreover, docking simulations were performed to reveal key interactions within the COX-1 binding pocket. Furthermore, the toxicity of the selected compounds was tested using the normal human kidney HK-2 cell line.
    Permanent Link: https://hdl.handle.net/11104/0341920

     
    FileDownloadSizeCommentaryVersionAccess
    2023_Sisa_ARCHIV DER PHARMAZIE_e2200549.pdf11.7 MBOtheropen-access
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.